Error message

Deprecated function: Using ${var} in strings is deprecated, use {$var} instead in include_once() (line 1442 of includes/bootstrap.inc).
Deprecated function: Using ${var} in strings is deprecated, use {$var} instead in include_once() (line 1442 of includes/bootstrap.inc).
Deprecated function: Optional parameter $type declared before required parameter $nid is implicitly treated as a required parameter in include_once() (line 1442 of includes/bootstrap.inc).

G 0005/83 (Second medical indication) of 5.12.1984

European Case Law Identifier:

ECLI:EP:BA:1984:G000583.19841205

Date of decision:

05 December 1984

Case number:

G 0005/83

Referral:

Application number:

IPC class:

-

Language of proceedings:

EN

Distribution:

A

Download and more information:

Decision text in EN (PDF, 668Â KB)
Documentation of the appeal procedure can be found in the Register
Bibliographic information is available in:	EN
Versions:	OJ \| Published

Title of application:

-

Applicant name:

EISAI

Opponent name:

-

Board:

EBA

Headnote:

I. A European Patent with claims directed to the use may not be granted for the use of a substance or composition for the treatment of the human or animal body by therapy.
II. A European patent may be granted with claims directed to the use of a substance or composition for the manufacture of a medicament for a specified new and inventive therapeutic application.

Relevant legal provisions:

European Patent Convention 1973 Art 52(1)
European Patent Convention 1973 Art 52(4)
European Patent Convention 1973 Art 54(5)
European Patent Convention 1973 Art 57
Vienna Convention on the Law of Treaties (1969) Art 31
Vienna Convention on the Law of Treaties (1969) Art 32

Keywords:

Interpretation of the EPC
Interpretation of the Vienna Convention
Therpeutical use claims
Second medical indication

Catchwords:

-

Cited decisions:

-

Citing decisions:

G 0001/98
G 0002/02
G 0003/02
G 0001/03
G 0002/03
G 0002/06
G 0001/07
G 0002/08
G 0003/08
G 0001/09
G 0002/12
G 0002/13
G 0001/18
J 0022/95
J 0032/95
J 0019/96
J 0009/98
J 0010/98
J 0040/03
J 0018/04
J 0008/07
J 0009/07
T 0261/87
T 0578/90
T 0438/91
T 0885/91
T 0585/92
T 0655/92
T 0820/92
T 0051/93
T 0074/93
T 0149/93
T 0167/93
T 0254/93
T 0590/93
T 1058/93
T 0067/94
T 0140/94
T 0143/94
T 0199/94
T 0329/94
T 0853/94
T 0958/94
T 0138/95
T 0150/95
T 0317/95
T 0919/95
T 0276/96
T 0532/96
T 0863/96
T 1054/96
T 0056/97
T 0584/97
T 0775/97
T 1209/97
T 0004/98
T 0315/98
T 0629/98
T 0904/98
T 0922/98
T 0035/99
T 0492/99
T 0800/99
T 0964/99
T 1031/00
T 1076/00
T 0445/01
T 0486/01
T 0836/01
T 1001/01
T 1066/01
T 0062/02
T 0138/02
T 0250/02
T 0609/02
T 0708/02
T 0801/02
T 0157/03
T 0383/03
T 0520/03
T 0741/03
T 0990/03
T 1020/03
T 1127/03
T 1172/03
T 1200/03
T 1229/03
T 0036/04
T 0154/04
T 0292/04
T 0358/04
T 0509/04
T 1011/04
T 1303/04
T 1319/04
T 1374/04
T 1399/04
T 0021/05
T 0250/05
T 0380/05
T 0501/05
T 0600/05
T 0639/05
T 1127/05
T 1286/05
T 1287/05
T 0049/06
T 0173/06
T 0188/06
T 0394/06
T 0406/06
T 0515/06
T 0699/06
T 0826/06
T 1031/06
T 1167/06
T 1242/06
T 0047/07
T 0213/07
T 0385/07
T 0566/07
T 0316/08
T 0491/08
T 1199/08
T 1798/08
T 2003/08
T 2181/08
T 0108/09
T 0611/09
T 1099/09
T 1150/09
T 1570/09
T 1729/09
T 1955/09
T 0270/10
T 0495/10
T 0773/10
T 0803/10
T 2221/10
T 2369/10
T 0053/11
T 0161/11
T 0171/11
T 0677/11
T 1021/11
T 1088/11
T 1107/11
T 1494/11
T 1554/11
T 1673/11
T 0879/12
T 1113/12
T 1278/12
T 1780/12
T 2017/12
T 2506/12
T 0714/13
T 1402/13
T 1553/13
T 1819/13
T 0013/14
T 0015/14
T 0081/14
T 0433/14
T 0899/14
T 1872/14
T 2251/14
T 0321/15
T 0563/15
T 1325/15
T 1758/15
T 2136/15
T 1186/16
T 2320/16
T 2491/16
T 0264/17
T 0304/17
T 1897/17
T 1695/18

Source: http://www.epo.org/law-practice/case-law-appeals/recent/g830005ex1.html

Date retrieved: 17 May 2021

143 references found.

Click X to load a reference inside the current page, click on the title to open in a new page.

EPO Guidelines - D Opposition and Limitation/Revocation Procedures

X GL D VII 8 Transitional provisions for Art. 54(4) EPC 1973 and Art. 54(5)

EPO Guidelines - G Patentability

X GL G II 4.2.1 Limitations of exception under Art. 53(c)

X GL G VI 7.1 First or further medical use of known products

X GL G VI 7.1.1 Products that may be claimed for a further medical use

EPO Guidelines - H Amendments and Corrections

X GL H V 7.3 Method claim to product claim

Offical Journal of the EPO

X OJ EPO SE 1/2021, p179 - Annex 1 - Index of published decisions of the boards of appeal and the Enlarged Board of Appeal - (as at 31 December 2020)

X OJ EPO SE 1/2020, p174 - Annex 1 - Index of published decisions of the boards of appeal and the Enlarged Board of Appeal - (as at 31 December 2019)

X OJ EPO 2020, A26 - Opinion of the Enlarged Board of Appeal dated 18 July 2019G 1/18

X OJ EPO SE 1/2019, p158 - XVI. - Index of published decisions of the boards of appeal and the Enlarged Board of Appeal - (as at 31 December 2018)

X OJ EPO SE 3/2018, p91 - ANNEX 2

X OJ EPO SE 3/2018, p2 - BOARDS OF APPEAL AND ENLARGED BOARD OF APPEAL CASE LAW 2017

X OJ EPO SE 4/2016, p258 - Notice from the European Patent Office dated 20 September 2010 concerning the non-acceptance of Swiss-type claims for second or further medical use following decision G 2/08 of the Enlarged Board of Appeal

X OJ EPO 2016, A27 - Decision of the Enlarged Board of Appeal dated 25 March 2015 - G 2/12

X OJ EPO SE 5/2014, p166 - ANNEX 2

X OJ EPO SE 5/2014, p25 - PART II

X OJ EPO 2014, A114 - Decision of the Enlarged Board of Appeal dated 30 April 2014 - G 1/12

X OJ EPO 2014, A84 - Interlocutory decision of Technical Board of Appeal 3.2.06 dated 20 February 2014

X OJ EPO 2014, A76 - Interlocutory decision of Technical Board of Appeal 3.5.06 dated 24 February 2014

Case Law Book: I Patentability

X CLR I A 1 Patent protection for technical inventions

X CLR I B 4.1 Introduction

X CLR I B 4.4.1.A Definition of the term

X CLR I C 7.1.1 Introduction

X CLR I C 7.2.1 Introduction

X CLR I C 7.2.4.I Discovery of a previously unknown property of a compound underlying the known effect

X CLR I C 7.2.4.A General

X CLR I C 7.2.4.B New therapeutic application based on the group of subjects to be treated

X CLR I C 7.2.4.C New technical effect

X CLR I C 7.2.4.D Same illness

X CLR I C 7.2.4.E New dosage regimen

X CLR I C 7.2.4.F New therapy with a different mode of administration

X CLR I C 7.2.4.G Interpretation of "substance or composition"

X CLR I C 7.2.4.J Whether there is a therapeutic method

X CLR I C 8.1.1 General issues decided before the Enlarged Board of Appeal

X CLR I C 8.1.4 Statement of purpose in non-medical use claims in view of Article 52(4) EPC 1973

Case Law Book: II Conditions to be met by an Application

X CLR II C 7.2 Level of disclosure required for medical use – plausibility

X CLR II E 2.6.5 From use claim to process claim, and vice versa

X CLR II E 2.6.6 From use claim to Swiss-type claim

Case Law Book: III Amendments

X CLR III H Interpretation of the EPC

X CLR III H 1 The Vienna Convention on the Law of Treaties

X CLR III H 1.1 Principles of interpretation of the Vienna Convention

X CLR III H 4.1 The duty of the boards of appeal to interpret and apply the EPC

X CLR III H 5 Decisions of the Administrative Council: boards of appeal not formally bound

Case Law of the Enlarged Board

X G 0001/98 (Transgenic plant/NOVARTIS II) of 20.12.1999

X G 0002/02 (Priorities from India/ASTRAZENECA) of 26.4.2004

X G 0003/02 (Priorities from India/ASTRAZENECA) of 26.4.2004

X G 0001/03 (Disclaimer/PPG) of 8.4.2004

X G 0002/03 (Disclaimer/GENETIC SYSTEMS) of 8.4.2004

X G 0002/06 (Use of embryos/WARF) of 25.11.2008

X G 0001/07 (Treatment by surgery/MEDI-PHYSICS) of 15.2.2010

X G 0002/08 (Dosage regime/ABBOTT RESPIRATORY) of 19.2.2010

X G 0003/08 (Programs for computers) of 12.5.2010

X G 0001/09 (Pending application/SONY) of 27.9.2010

X G 0002/12 () of 25.3.2015

X G 0002/13 () of 25.3.2015

X G 0001/18 (Filing an appeal) of 18.7.2019

General Case Law

X J 0022/95 (Designation of Contracting States in divisional application) of 4.7.1997

X J 0032/95 (Power of Exam. Div.to refuse reimbursement of appeal fee) of 24.3.1999

X J 0019/96 (No designation in divisional) of 23.4.1999

X J 0010/98 (Priority from India/ASTRAZENECA) of 2.12.2002

X J 0040/03 (Divisional/YAZAKI) of 18.8.2004

X J 0018/04 (Concept of time limit/MICROSOFT) of 4.5.2005

X J 0008/07 (Langue de la procÃ©dure) of 1.7.2010

X J 0009/07 (Priority period and re-establishment/TOSHIBA) of 30.6.2008

X T 0261/87 () of 16.12.1988

X T 0438/91 (Feeds/MEIJI) of 17.10.1994

X T 0585/92 (Deodorant detergent) of 9.2.1995

X T 0820/92 (Contraceptive method) of 11.1.1994

X T 0051/93 (HCG/SERONO) of 8.6.1994

X T 0074/93 (Contraceptive method) of 9.11.1994

X T 0149/93 (RETINOIDS/Kligman II) of 23.3.1995

X T 0167/93 (Bleaching agents) of 3.5.1996

X T 0254/93 (Prevention of skin atrophy) of 14.5.1997

X T 0590/93 (Photosensitive resins) of 10.5.1994

X T 0143/94 (Trigonelline) of 6.10.1995

X T 0317/95 (Gastrointestinal compositions/PROCTER & GAMBLE) of 26.2.1999

X T 0919/95 (Schutzbeschichtung/SIEMENS) of 16.1.1997

X T 0276/96 () of 17.6.1997

X T 0056/97 ("Thiazide diuretics"/EURO-CELTIQUE) of 30.8.2001

X T 0584/97 (Use of nicotine/ELAN CORPORATION) of 5.12.2001

X T 0775/97 () of 3.4.2001

X T 0004/98 (Liposome Compositions/SEQUUS) of 9.8.2001

X T 0035/99 (Pericardial access/GEORGETOWN UNIVERSITY) of 29.9.1999

X T 1031/00 () of 23.5.2002

X T 1076/00 (Impfstoff gegen Drogen/CHILKA Ltd.) of 5.8.2003

X T 0486/01 (IGF-1/GENENTECH, INC., et al) of 3.9.2003

X T 0836/01 (Interferon-beta2/YEDA RESEARCH AND DEVELOPMENT CO. LTD.) of 7.10.2003

X T 1001/01 (Treatment of ovarian cancer/SMITHKLINE BEECHAM CORPORATION) of 11.10.2007

X T 0138/02 () of 27.6.2006

X T 0250/02 (Pharmaceutical Compositions/NITSAS) of 28.4.2005

X T 0609/02 (AP-1 complex/SALK INSTITUTE) of 27.10.2004

X T 0801/02 (Sulfonamides/SEARLE) of 29.6.2005

X T 0157/03 (Reducing blood loss/ZYMOGENETICS) of 4.1.2005

X T 0383/03 (Hair removal method/THE GENERAL HOSPITAL CORP.) of 1.10.2004

X T 1020/03 (Method of administration of IGF-I/GENENTECH INC.) of 29.10.2004

X T 1172/03 () of 4.5.2005

X T 1200/03 () of 15.6.2005

X T 0154/04 (Estimating sales activity / DUNS LICENSING ASSOCIATES) of 15.11.2006

X T 0358/04 (Retroviral protease inhibitors/G.D. SEARLE) of 6.12.2006

X T 0509/04 (Cerebral palsy/ALLERGAN) of 5.7.2005

X T 1319/04 (Dosage regimen/KOS LIFE SCIENCES, INC.) of 22.4.2008

X T 1374/04 (Stem cells/WARF) of 7.4.2006

X T 1399/04 (Combination therapy HCV/SCHERING) of 25.10.2006

X T 0021/05 (CTL responses to HCV/SCRIPPS) of 13.7.2006

X T 0250/05 (Use of nitric oxide for systemic treatment/THE BRIGHAM AND WOMEN' … of 4.3.2008

X T 0380/05 (GnRH Antagonists/PRAECIS) of 13.4.2006

X T 1127/05 (Inhibition of angiogenesis/SCRIPPS RESEARCH INSTITUTE) of 15.1.2008

X T 0406/06 (Stimulation of beta cell proliferation/NOVO NORDISK) of 16.1.2008

X T 0515/06 (Probiotics/NESTEC) of 18.1.2007

X T 0699/06 (Morphogenesis/STRYKER) of 29.6.2010

X T 1167/06 () of 26.7.2007

X T 1242/06 (Tomatoes II/STATE OF ISRAEL) of 31.5.2012

X T 0385/07 (Aplidine/PHARMA MAR) of 5.10.2007

X T 0491/08 (Improved immunogenicity/GOVERNMENT USA) of 21.10.2010

X T 1199/08 (Selected sperm/XY) of 3.5.2012

X T 1798/08 () of 21.8.2012

X T 2003/08 (Dilated cardiomyopathy/EDWARDS) of 31.10.2012

X T 2181/08 (TREM-1 splice variant/GENEPRINT) of 14.11.2012

X T 0108/09 (Fulvestrant for treating resistant breast cancer/ASTRA ZENECA AB) of 14.2.2013

X T 0611/09 (Catheter lock solution/ASH ACCESS TECHNOLOGY, INC.) of 18.10.2011

X T 1099/09 () of 12.1.2012

X T 1570/09 (Alpha-ketoglutaric acid and pharmaceutically acceptable salts thereof … of 16.5.2014

X T 1955/09 (Antimicrobial peptides/OCTOPLUS SCIENCES) of 12.6.2013

X T 0495/10 () of 3.7.2012

X T 0773/10 () of 24.10.2014

X T 2221/10 (Culturing stem cells/TECHNION) of 4.2.2014

X T 2369/10 () of 13.11.2015

X T 1021/11 (PCV2 composition/BOEHRINGER INGELHEIM) of 2.6.2015

X T 1088/11 () of 17.6.2016

X T 1673/11 (Treatment of Pompe's disease/GENZYME) of 20.10.2015

X T 0879/12 (APO-2 ligand/GENENTECH) of 27.8.2014

X T 1278/12 () of 28.4.2015

X T 1780/12 (Cancer treatment/BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM) of 30.1.2014

X T 2017/12 () of 24.2.2014

X T 1402/13 (Appeal fee/GBC METALS) of 31.5.2016

X T 1553/13 (Inadmissibility of an appeal where the appeal fee is paid after … of 20.2.2014

X T 1819/13 () of 21.2.2018

X T 0013/14 (Agent for treatment of schizophrenia/SUMITOMO DAINIPPON) of 15.10.2015

X T 0015/14 (Immunemodulating oligosaccharides for use in medical treatment/ … of 6.10.2015

X T 0081/14 () of 12.3.2015

X T 2251/14 () of 10.7.2018

X T 1325/15 (Location-based searches/QUALCOMM) of 7.6.2016

X T 1758/15 () of 11.7.2017

X T 1897/17 () of 14.2.2018